Welcome to our dedicated page for Immunovant SEC filings (Ticker: IMVT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Immunovant, Inc. filings document the formal disclosures of a clinical-stage immunology company developing anti-FcRn product candidates for autoimmune diseases. Recent Form 8-K reports cover quarterly financial results, operating updates, research and development activity, clinical program communications for Graves’ disease and related indications, financing disclosure and other material events.
Proxy and governance filings describe annual meeting matters, director elections, auditor ratification, executive compensation, equity awards and stockholder voting results. Officer-transition and compensation-related 8-Ks add detail on employment agreements, severance arrangements, consulting services and incentive awards, while the company’s disclosures frame capital structure and governance around its single development-focused operating segment.
Immunovant, Inc. director Atul Pande reported an option exercise and share sale. On May 20, 2026, he exercised stock options to acquire 6,000 shares of common stock at $8.43 per share and sold 6,000 shares at $32.00 per share.
After these transactions, he directly holds 116,731 common shares and indirectly holds 20,000 shares through a trust. A related footnote states the sale occurred under a pre-arranged Rule 10b5-1 trading plan, indicating the timing was planned in advance.
Immunovant, Inc. is a clinical-stage immunology company focused on IMVT-1402 (imeroprubart), a fully human anti‑FcRn antibody intended to treat IgG‑mediated autoimmune diseases across endocrinology, neurology, rheumatology and dermatology.
Phase 1 data in healthy adults showed deep, dose‑dependent IgG reductions, supporting a potential best‑in‑class profile with subcutaneous self‑administration via an autoinjector. The company has ongoing studies in six indications, including potentially registrational trials in Graves’ disease, difficult‑to‑treat rheumatoid arthritis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy and Sjögren’s disease, plus a proof‑of‑concept trial in cutaneous lupus erythematosus.
In April 2026, top‑line Phase 3 results for its first‑generation antibody batoclimab in thyroid eye disease failed to meet the primary endpoint, and Immunovant decided to discontinue batoclimab development to concentrate resources on IMVT‑1402 while leveraging prior clinical and operational learnings.
Immunovant, Inc. reported corporate updates and financial results for its fourth quarter and fiscal year ended March 31, 2026. Lead asset IMVT-1402 showed encouraging preliminary results in difficult-to-treat rheumatoid arthritis, with Week 16 ACR20, ACR50 and ACR70 response rates of 72.7%, 54.5% and 35.8% in the open-label period. A proof-of-concept trial in cutaneous lupus erythematosus is fully enrolled, and potentially registrational studies in Graves’ disease, myasthenia gravis, CIDP and Sjögren’s disease remain on track, with multiple topline readouts expected in 2026–2027. The company discontinued batoclimab after two Phase 3 thyroid eye disease trials did not meet their primary endpoint and is redirecting resources to IMVT-1402.
For the quarter, research and development expenses were $142.3 million and net loss was $147.9 million, or $0.73 per share. For the full fiscal year, research and development expenses were $456.7 million and net loss was $505.6 million, or $2.77 per share. Cash and cash equivalents totaled $902.1 million as of March 31, 2026, which management states provide runway through the potential commercial launch of IMVT-1402 in Graves’ disease.
Immunovant, Inc. director Robert Graham Susman reported an open-market sale of 2,502 shares of common stock at a weighted average price of $27.17 per share. The transaction was executed under a Rule 10b5-1 trading plan adopted on December 30, 2025.
Following this sale, he directly holds 36,394 shares of Immunovant common stock, so the filing reflects a partial reduction rather than an exit from his position.
Immunovant, Inc. Chief Financial Officer Tiago Girao reported an open-market sale of 25,760 shares of common stock at a weighted average price of $29.62 per share. After this transaction, he directly holds 247,596 shares.
According to the footnotes, this sale was executed solely to cover tax withholding obligations tied to the vesting and settlement of 52,097 restricted stock units from a prior grant of 208,388 RSUs. The company required a “sell to cover” transaction, so the sale is described as non-discretionary for the executive.
Immunovant, Inc. Chief Technology Officer Jay S. Stout reported an open-market sale of 2,754 shares of common stock at a weighted average price of $29.62 per share. According to the footnotes, these shares were sold solely to cover tax withholding obligations from the vesting of previously granted RSUs.
The sale was mandated by the company’s “sell to cover” election and is described as not a discretionary transaction by the executive. Following the sale, Stout directly owns 251,685 shares of Immunovant common stock.
Immunovant, Inc. Chief Legal Officer Christopher Van Tuyl reported an open-market sale of 5,165 shares of common stock on April 8, 2026 at a weighted average price of $24.83 per share. According to the disclosure, this sale was required to cover tax withholding obligations tied to the vesting and settlement of previously granted restricted stock units and was not a discretionary trade. Following the transaction, Van Tuyl directly holds 183,231 shares of Immunovant common stock.
Immunovant, Inc. Chief Operating Officer Gloria Melanie reported an open-market sale of 8,722 shares of common stock at a weighted average price of $24.83 per share. According to the filing, this sale was mandated as a “sell to cover” transaction to satisfy tax withholding obligations from the vesting and settlement of previously granted restricted stock units. On April 1, 2025, she was granted 76,181 RSUs, of which 19,045 RSUs vested on April 1, 2026. Following the sale, she directly holds 245,222 shares of Immunovant common stock.